Efficacy of immunoconjugates in Her2+ breast cancer confirmed

They identify a new mechanism of trastuzumab resistance in HER2+ breast cancer

Exosomal RNA promotes HER2 expression and spread of resistance to other tumor cells, with implications for the design of resensitization strategies. + read more

Positive results of pyrotinib and nab-paclitaxel in HER2+ breast cancer

Preliminary data from a phase II study show that this combination benefits patients with metastatic disease and prior treatment with trastuzumab. + read more

Novel Anti-Her2 Agent Capable of Reaching Brain Metastases

The first clinical trial of DZD1516 identified the maximum tolerated dose and demonstrated the drug’s potential to combat intracranial disease in breast cancer. + read more

Positive results of trastuzumab deruxtecan in HER2-low RH+ metastatic breast cancer

Results from the Phase III DESTINY-Breast06 study led by Daiichi Sankyo Alliance | AstraZeneca reports that trastuzumab deruxtecan demonstrates statistically and clinically meaningful improvement in progression-free survival compared with standard chemotherapy in patients with very low HER2 expression (HER2-ultra-low-IHC1+ or IHC 2+/ISH-) + more

New Combination With Hormonal Therapy Trastuzumab and Palbociclib Reduces Risk of Breast Cancer Progression by 48%

SOLTI presented the PATRICIA study, the first study to perform molecular selection of patients with advanced breast cancer. The results were very positive, as it demonstrated that the prognostic value allows to propose new, less toxic treatment alternatives, with greater efficacy and better tolerability. + read more

New drug improves survival in women with metastatic breast cancer

According to DESTINY-Breast03, about 70% of women with metastatic or unresectable breast cancer are still alive after three years of treatment with trastuzumab deruxtecan. The study is a phase III, multicenter, randomized clinical trial and included 524 patients who had previously undergone two lines of treatment. + read more